Trevi Therapeutics, Inc. (TRVI)
NASDAQ · Manufacturing · Pharmaceutical preparations
$14.00−$0.6749 (−4.60%) on the dayAs of the close; data may be delayed.
TRVI price, last 12 months
Key stats
- Previous close
- $14.68
- Open
- $14.68
- Day range
- $14.00 – $14.75
- 52-week range
- $8.24 – $20.22
- Volume
- 1.1M
- Avg volume (20 days)
- 1.5M
- Market cap
- $2.1B
Performance
1W−6.4%
1M−21.9%
3M−22.9%
6M+18.6%
YTD+11.8%
1Y+65.3%
vs S&P 500, 1Y+48.5 pts
Technicals and fundamentals
About Trevi Therapeutics, Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.1B